[Enfortumab vedotin (urothelial cancer) - 2nd addendum to commission A22-61]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004301
Original Title: Enfortumab Vedotin (Urothelkarzinom) - 2. Addendum zum Auftrag A22-61
Project Status: Completed
Year Published: 2022
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Urologic Neoplasms
  • Carcinoma, Transitional Cell
  • Immunoconjugates
  • Urinary Bladder Neoplasms
  • Antibodies, Monoclonal
  • Enfortumab Vedotin
  • Urologic Neoplasms
  • Carcinoma - Transitional Cell
  • Benefit Assessment
  • NCT03474107
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.